Sesen Bio, Inc.
(NASDAQ : EBIO)

( )
EBIO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.37%86.271.3%$1352.68m
AMGNAmgen Inc.
0.97%203.881.2%$612.82m
GILDGilead Sciences, Inc.
0.77%69.180.9%$531.67m
LOXOLoxo Oncology Inc
0.11%233.5012.7%$525.80m
BIIBBiogen Inc.
-0.27%337.421.3%$408.79m
VRTXVertex Pharmaceuticals Incorporated
2.19%194.701.9%$323.01m
ILMNIllumina, Inc.
0.87%312.753.5%$317.65m
REGNRegeneron Pharmaceuticals, Inc.
0.35%418.842.6%$300.57m
ALXNAlexion Pharmaceuticals, Inc.
2.12%117.052.0%$212.97m
TSROTESARO, Inc.
0.03%74.9614.4%$167.91m
INCYIncyte Corporation
-0.32%78.422.5%$149.05m
AAgilent Technologies, Inc.
2.10%72.311.5%$147.46m
EXASExact Sciences Corporation
4.19%78.8025.3%$141.72m
SRPTSarepta Therapeutics, Inc.
1.22%122.8015.4%$135.00m
LGNDLigand Pharmaceuticals Incorporated
6.49%117.9023.1%$126.49m

Company Profile

Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.